Nanotechnology approaches for personalized treatment of multidrug resistant cancers

被引:123
作者
Minko, Tamara [1 ,2 ]
Rodriguez-Rodriguez, Lorna [2 ,3 ]
Pozharov, Vitaly [1 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Obstet & Gynecol, New Brunswick, NJ 08901 USA
关键词
Passive and active targeting; Drug delivery system; Pump and nonpump resistance; Antibody; siRNA; Antisense oligonucleotides; Peptides; Cancer stem cells; LHRH; CD44; DRUG-DELIVERY-SYSTEM; MULTIFUNCTIONAL NANOMEDICINE PLATFORM; ANTIAPOPTOTIC CELLULAR DEFENSE; CISPLATIN-INDUCED APOPTOSIS; HYPOXIA INDUCIBLE FACTOR; ANTICANCER DRUG; LUNG-CANCER; ANTISENSE OLIGONUCLEOTIDES; FREE-RADICALS; CO-DELIVERY;
D O I
10.1016/j.addr.2013.09.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of chemotherapy is substantially limited by the resistance of cancer cells to anticancer drugs that fluctuates significantly in different patients. Under identical chemotherapeutic protocols, some patients may receive relatively ineffective doses of anticancer agents while other individuals obtain excessive amounts of drugs that induce severe adverse side effects on healthy tissues. The current review is focused on an individualized selection of drugs and targets to suppress multidrug resistance. Such selection is based on the molecular characteristics of a tumor from an individual patient that can potentially improve the treatment outcome and bring us closer to an era of personalized medicine. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1880 / 1895
页数:16
相关论文
共 156 条
  • [1] Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer
    Abbasi, Meysam
    Lavasanifar, Afsaneh
    Uludag, Hasan
    [J]. MEDICINAL RESEARCH REVIEWS, 2013, 33 (01) : 33 - 53
  • [2] Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
    Abraham, Ioana
    El Sayed, Khalid
    Chen, Zhe-Sheng
    Guo, Huiqin
    [J]. MARINE DRUGS, 2012, 10 (10) : 2312 - 2321
  • [3] Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells
    Akagi, Hideko
    Higuchi, Hajime
    Sumimoto, Hidetoshi
    Igarashi, Toru
    Kabashima, Ayano
    Mizuguchi, Hiroyuki
    Izumiya, Motoko
    Sakai, Gen
    Adachi, Masayuki
    Funakoshi, Shinsuke
    Nakamura, Shoko
    Hamamoto, Yasuo
    Kanai, Takanori
    Takaishi, Hiromasa
    Kawakami, Yutaka
    Hibi, Toshifumi
    [J]. GASTRIC CANCER, 2013, 16 (01) : 100 - 110
  • [4] The philosophy behind exo/endo/existing antioxidants and our built-in oxidant and antioxidant system
    Amara, A. A.
    [J]. PHARMAZIE, 2010, 65 (10): : 711 - 719
  • [5] Bae M, 2003, DRUG EXP CLIN RES, V29, P15
  • [6] Recent Advances in the Development of P-gp Inhibitors
    Baumert, Christiane
    Hilgeroth, Andreas
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (04) : 415 - 436
  • [7] Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy
    Behnam-Motlagh, Parviz
    Tyler, Andreas
    Grankvist, Kjell
    Johansson, Anders
    [J]. TOXINS, 2010, 2 (10) : 2467 - 2477
  • [8] Treatment of Persistent Asthma With Symbicort® (Budesonide/Formoterol Inhalation Aerosol): An Inhaled Corticosteroid and Long-Acting β2-Adrenergic Agonist in One Pressurized Metered-Dose Inhaler
    Berger, William E.
    Noonan, Michael J.
    [J]. JOURNAL OF ASTHMA, 2010, 47 (04) : 447 - 459
  • [9] New hope in the horizon: cancer stems cells
    Bhattacharyya, Shalmoli
    Khanduja, Kishan Lal
    [J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2010, 42 (04) : 237 - 242
  • [10] Bounous G, 2003, ANTICANCER RES, V23, P1411